후원로펌 뉴스레터

본문 바로가기

HOME > 후원로펌 현황 > 후원로펌 뉴스레터

후원로펌 현황

[법무법인 광장] Transition to a Negative Regulatory Framework for In Vitro Diagnostic (IVD) Medical Devices

페이지 정보

작성일18-11-27 16:06

본문


상단 이미지

Transition to a Negative Regulatory Framework 
for In Vitro Diagnostic (IVD) Medical Devices

The 55th Policy meeting was held on October 31, 2018, presided by Prime Minister Nak-yeon Lee. This conference was attended by the heads of administrative agencies, such as the Ministry of Health and Welfare(MHW) and the Ministry of Food and Drug Safety(MFDS), to discuss and confirm the 「Comprehensive Negative Regulatory Transition Performance Results and Future Plans」.


1. Comprehensive Negative Regulatory Transition

The comprehensive negative regulatory transition is a transition into a ‘approve first – regulate later’ system for new businesses by changing the existing positive method of regulation, which requires that new technology must either comply with regulations that already exist (which are not compatible with the new technology) or wait for the government to devise rules that specifically allow that new technology.  Under the negative regulatory framework, the new technology can enter the market with relevant changes in regulations to follow, as necessary.  By drastically reducing the time it takes for new technology to enter the market, the reform hopes to strengthen emerging business sectors that are driving the 4th industrial revolution.


2. Regulatory Innovation in the Field of Medical Devices

The medical device sector is the main target industry of the comprehensive negative regulatory transition. On July 19, 2018, the relevant government agencies made a joint announcement on Regulatory Innovation in the Medical Device Industry and Measures to Promote Industry Development for Innovative Growth and Expansion」.

Among the key stated objectives of the regulatory innovation in the medical device industry is the Introduction of Comprehensive Negative Regulation for Safe Medical Devices.” And with respect to IVD medical devices, the plan is to (1) switch the evaluation of new medical technology from pre-market evaluation to post -market evaluation, and (2) exempt the approval requirement for changes except for those that are significant.


3. Comprehensive Negative Regulatory Transition for IVD Medical Devices

(1)Post-Market Evaluation of New Medical Technology

Starting from January of 2019, the MHW will first begin by exempting the pre-market evaluation process for infectious disease IVD medical devices. The MHW has announced that it plans to eventually extend the exemption to all IVD medical devices.

(2)Exemption of Approval for Change except for Significant Changes

The MFDS has announced its plan to exempt the approval requirement for changes for IVD medical devices, except for those that involve significant changes.

According to the current 「Regulations on Medical Device Approval, Notification, and Review」 (MFDS Notification No. 2018-59), the 140 items in 10 different categories listed under [Attachment 3] ‘Minor Changes’ are exempt from approval requirement for changes.

However, the MFDS plans to amend Regulations on Medical Device Approval, Notification, and Review」 so that, beginning February of 2019, (i) the approval requirement for all changes that are not significant will be exempted, and (ii) manufacturers and importers only have to report to the MFDS after-the-fact for such non-significant changes.

As a result of these amendments, it is expected that manufacturers and importers of IVD medical devices will be able to enjoy a cut-back of 2 or more months in the change approval process as well as a significant reduction in fees for change approval.

─ CONTACT ─
변호사 이형근
Hyeong Gun LEE
T:82.2.772.4379
E:hyeonggun.lee
@leeko.com
profile>
Keum Nang PARK
Keum Nang PARK
T:82.2.2191.3036
E:keumnang.park
@leeko.com
profile>
변호사 신재영
Eileen Jaiyoung SHIN
T:82.2.772.4831
E:eileen.shin
@leeko.com
profile>

 

For more information pertaining to this newsletter, please contact the attorneys identified on the right.
The Lee&Ko Legal Newsletter is provided for general information purposes only and should not be considered as the considered as the rendering of legal advice for any specific matter. If you no longer wish to receive our newsletter service, please click here or reply to this email stating UNSUBSCRIBE in the subject line. The contects and opinions expressed in the Lee&Ko Legal Newsletter are protected by law against any unauthorized use.
후원로펌 뉴스레터 목록
번호 제목 날짜
2507 [법무법인(유) 율촌] 프랑스 정부, 전기차 구매보조금 지급 정책 개편 - 생산에 수반되는 탄소발자국 반영 2024-02-23
2506 [법무법인(유) 율촌] 율촌 입법 위클리 2024-06호 첨부파일 2024-02-23
2505 [법무법인(유) 화우] 가상융합산업 진흥법(메타버스 산업 진흥을 위한 법률) 제정 2024-02-23
2504 [법무법인(유) 화우] 개인정보위, 2024년 조사업무 추진방향 발표 2024-02-23
2503 [법무법인(유) 화우] 저성과자 해고의 정당성 판단 2024-02-23
2502 [법무법인(유) 화우] 문체부, 확률형 아이템 확률 정보공개 관련 해설서 발표 2024-02-23
2501 [법무법인(유) 화우] EU 이사회, 강제노동 제품 금지 관련 법안 입장 확정 2024-02-23
2500 [법무법인(유) 화우] 대주주적격성유지요건 충족명령 미이행에 따른 주식처분명령 취소 판결(서울행정법원) 2024-02-23
2499 [법무법인(유한) 태평양] 식약처, 2024년 주요 업무 추진계획 발표 – 「식의약 안심이 일상이 되는 세상」 2024-02-22
2498 [법무법인(유) 광장] PIPC Announces Policy Direction for the Protection of Online Behavioral Data Used in Targeted Advertising 2024-02-22
2497 [법무법인(유한) 대륙아주] Weekly_Legislative_Report_Week_of_February_12_to_February_16_2024 2024-02-22
2496 [법무법인(유한) 바른] 뉴스레터 - 제129호(2024.2) 2024-02-21
2495 [법무법인(유) 광장] 국토계획법 개정안 공포_융복합 도시공간 조성을 위한 제도 개선 2024-02-21
2494 [법무법인(유한) 대륙아주] AI 이슈리포트 - 유럽연합, AI 규제법안에 대하여 전격 합의 2024-02-21
2493 [법무법인(유한) 대륙아주] 아프리카 이슈리포트_한국의 핵심광물 공급망 다변화 및 아프리카 핵시 2024-02-21
게시물 검색

사단법인 인하우스카운슬포럼 In-House Counsel Forum

주소 : 서울시 강남구 테헤란로 625, 17층 | 고유번호 : 107-82-14795

E-mail : reps@ihcf.co.kr

Copyright(C) IHCF KOREA. ALL RIGHTS RESERVED.

모바일 버전으로 보기